Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 2Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Lymphoid 1Dermatologic 1

Conditions

Breast Neoplasms 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Small Cell Lung Carcinoma 1Mycosis Fungoides 1Multiple Myeloma 1Mesothelioma, Malignant 1Mesothelioma 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell, Marginal Zone 1Inflammatory Breast Neoplasms 1Hodgkin Disease 1Esophageal Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1

Interventions

Trastuzumab 78Capecitabine 59Cyclophosphamide 54Paclitaxel 52Docetaxel 50Letrozole 44Fulvestrant 43Lapatinib 34Doxorubicin 31Carboplatin 31Vinorelbine 30Bevacizumab 29Anastrozole 28pembrolizumab 26exemestane 24Tamoxifen 23Gemcitabine 22Radiotherapy 21Albumin-Bound Paclitaxel 19Taxes 17Everolimus 17Epirubicin 15pertuzumab 13Ado-Trastuzumab Emtansine 13130-nm albumin-bound paclitaxel 13palbociclib 12Magnetic Resonance Spectroscopy 12liposomal doxorubicin 11atezolizumab 11Filgrastim 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Breast Neoplasms × Depsipeptides × Clear all
NCT03432741 2025-05-26

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Mayo Clinic

Phase 1 Terminated
17 enrolled
BreastDermatologicLymphoid

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

NCT01938833 2025-05-16

Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer

Thomas Jefferson University

Phase 1/2 Terminated
9 enrolled 7 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡